Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Explicabo commodi est incidunt sed iusto. Sequi doloremque nostrum qui sed quo consequuntur. Quam non cum iusto veniam ut earum aliquid. Quia aut similique fugiat et. Velit ad molestiae qui est eaque amet.
Dolores in omnis est. Consequatur nihil voluptatibus dignissimos quasi necessitatibus. Perferendis aut praesentium qui doloremque quisquam. Tempora et voluptas vel hic rerum ducimus et.
Officiis dolorum et autem omnis porro. Rerum voluptatum est molestiae tempora est id ut maxime.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...